DRUG vs MNPR

Comparison between Bright Minds Biosciences Inc (DRUG, Company) and Monopar Therapeutics Inc (MNPR, Company).

Both DRUG and MNPR are from the Healthcare sector.

5-Year PerformanceMNPR has outperformed DRUG, delivering a return of +32.0% compared to +28.2%

DRUG vs MNPR - Performance Comparison

Log

Key Characteristics

Financial metrics and valuation ratios

Metric	DRUG(COMPANY)	MNPR(COMPANY)
Market Cap	$728M	$728M
Max Drawdown	97.68%	98.93%
Sharpe Ratio	1.76	1.38
5Y Beta	-0.81	1.67
Industry	Biotechnology	Biotechnology
P/E Ratio	-30.85	-47.78
PEG Ratio	-0.08	N/A
5Y EPS CAGR	8.42%	-5.81%
Debt to Equity	0.03%	0.00%
Free Cash Flow Yield	-2.00%	-1.38%
P/B Ratio	3.34	4.94

Market Cap

DRUG

$728M

Winner

MNPR

$728M

Max Drawdown

Winner

DRUG

97.68%

MNPR

98.93%

Sharpe Ratio

Winner

DRUG

1.76

MNPR

1.38

5Y Beta

Winner

DRUG

-0.81

MNPR

1.67

Industry

DRUG

Biotechnology

MNPR

Biotechnology

P/E Ratio

DRUG

-30.85

Winner

MNPR

-47.78

PEG Ratio

DRUG

-0.08

MNPR

N/A

5Y EPS CAGR

Winner

DRUG

8.42%

MNPR

-5.81%

Debt to Equity

DRUG

0.03%

Winner

MNPR

0.00%

Free Cash Flow Yield

DRUG

-2.00%

Winner

MNPR

-1.38%

P/B Ratio

Winner

DRUG

3.34

MNPR

4.94

DRUG vs MNPR - Historical Returns

Returns include dividend reinvestment.

Period	DRUG	MNPR
1 month	+23.00%	+56.96%
3 months	-17.82%	+93.60%
6 months	-10.11%	+50.60%
1 year	+185.42%	+128.09%
5 years(CAGR)	+28.20%	+31.98%
Max(CAGR)	+21.02%	-3.35%

DRUG

+23.00%

Winner

MNPR

+56.96%

DRUG

-17.82%

Winner

MNPR

+93.60%

DRUG

-10.11%

Winner

MNPR

+50.60%

Winner

DRUG

+185.42%

MNPR

+128.09%

5Y(CAGR)

DRUG

+28.20%

Winner

MNPR

+31.98%

Max(CAGR)

Winner

DRUG

+21.02%

MNPR

-3.35%

DRUG vs MNPR - Annual Returns (2019 - 2026)

Returns include dividend reinvestment.

Year	DRUG	MNPR
2026	-10.60%	+60.43%
2025	+89.83%	+193.88%
2024	+1859.10%	+1089.19%
2023	-63.33%	-85.34%
2022	-78.04%	-30.29%
2021	-41.30%	-49.53%
2020	N/A	-64.56%
2019	N/A	-37.36%

DRUG vs MNPR Drawdown Comparison

The maximum drawdown for DRUG was -97.68%, occurring on Jul 11, 2024. Recovery took 740 trading sessions.

The maximum drawdown for MNPR was -98.93%, occurring on Nov 20, 2023. This drawdown has not yet recovered.

The current DRUG drawdown is -22.27%. The current MNPR drawdown is -21.56%.

Rank	DRUG	MNPR
#1	-97.68% Nov 8, 2021 - Oct 18, 2024	-98.93% Dec 20, 2019 - Nov 20, 2023
#2	-58.28% Nov 6, 2024 - Sep 29, 2025	N/A
#3	-38.35% Jan 7, 2026 - Jun 15, 2026	N/A
#4	-27.84% Mar 22, 2021 - Aug 24, 2021	N/A
#5	-26.13% Oct 21, 2025 - Nov 28, 2025	N/A
#6	-19.30% Dec 16, 2025 - Jan 7, 2026	N/A
#7	-16.21% Sep 30, 2025 - Oct 9, 2025	N/A
#8	-14.42% Oct 11, 2021 - Nov 3, 2021	N/A
#9	-9.05% Oct 24, 2024 - Nov 4, 2024	N/A
#10	-7.65% Oct 14, 2025 - Oct 21, 2025	N/A
#11	-5.42% Dec 11, 2025 - Dec 16, 2025	N/A
#12	-4.62% Sep 24, 2021 - Sep 29, 2021	N/A
#13	-4.59% Dec 8, 2025 - Dec 10, 2025	N/A
#14	-4.38% Aug 24, 2021 - Sep 1, 2021	N/A
#15	-3.81% Sep 1, 2021 - Sep 17, 2021	N/A